Archive for the ‘Precision Cancer Medicine’ Category
Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI in Health, Life Sciences & BioPharma
Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence - General, Artificial Intelligence Applications in Health Care, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Drug Delivery Platform Technology, Drug Development Process, Drug Discovery Chemistry, drug repurposing, Genetics & Pharmaceutical, Global Market of Medical Devices Technology, Global Partnering & Biotech Investment, HealthCare IT, Personalized and Precision Medicine & Genomic Research, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Pharmacogenomics, Precision Cancer Medicine, Rapid automation of plasma protein pools on June 15, 2026|
Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session October 4 2025
Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence Applications in Health Care, Artificial Intelligence in CANCER, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Bio-Ethics, BioBanking, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Biological Networks, Biological Networks, Gene Regulation and Evolution, Cancer Genomics, Cancer Informatics, Clinical Diagnostics, Foundations for supporting Science and Education, Gene Regulation, Health Care System by Country, India, Intelligent Information Systems, Machine Learning, Natural Language Processing (NLP), Personalized and Precision Medicine & Genomic Research, Personalized Medicine Coalition, Precision Cancer Medicine, Proteomics, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, tumor microenvironment, tagged access to care, AI in Healthcare, Artificial Intelligence & Clinical Trials, Artificial Intelligence ( AI), artificial intelligence in drug design, bioethics, Biomarker discovery, biomarker panels, biomarkers panels, cancer centers, cancer consortium, cancer diagnostics, deep learning in drug discovery, Fox Chase Cancer Center, gastrointestinal carcinomas, Genentech, health disparities, healthcare delivery, immunooncology, India, molecular tumor board, Predictive Cancer Biomarkers on October 4, 2025| Leave a Comment »
Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session October 4 2025
Reporter: Stephen J. Williams, PhD
Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at
using the following meeting hashtags
#AdvancingPM #precisionmedicine #WINSYMPO2025
1:40 – 2:30
AI in Precision Medicine
- AI will help reduce time for drug development especially in early phase of discovery but eventually help in all phases
- Ganhui: for drug regulators might be more amenable to AI in clinical trials; AI may be used differently by clinicians
- nonprofit in Philadelphia using AI to repurpose drugs (this site has posted on this and article will be included here)
- Ganhui: top challenge of AI in Pharma; rapid evolution of AI and have to have core understanding of your needs and dependencies; realistic view of what can be done; AI has to have iterative learning; also huge vertical challenge meaning how can we allign the use of AI through the healthcare vertical layer chain like clinicians, payers, etc.
- Ganhui sees a challenge for health companies to understand how to use AI in business to technology; AI in AI companies is different need than AI in healthcare companies
- 95% of AI projects not successful because most projects are very discrete use
2:00-2:20
Building Precision Oncology Infrastructure in Low- and Middle-Income Countries
- globally 60 precision initiatives but there really are because many in small countries
- three out of five individuals in India die of cancer
- precision medicine is a must and a hub and spoke model is needed in these places; Italy does this hub and spoke; spokes you enable the small places and bring them into the network so they know how and have access to precision medicine
- in low income countries the challenge starts with biopsy: then diagnosis and biomarker is issue; then treatment decision a problem as they may not have access to molecular tumor boards
- prevention is always a difficult task in LMICs (low income)
- you have ten times more patients in India than in US (triage can be insurmountable)
- ICGA Foundation: Indian Cancer Genome Atlas
- in India mutational frequencies vary with geographical borders like EGFR mutations or KRAS mutations
- genomic landscape of ovarian cancer in India totally different than in TCGA data
- even different pathways are altered in ovarian cancer seen in North America than in India
- MAY mean that biomarker panels need to be adjusted based on countries used in
- the molecular data has to be curated for the India cases to be submitted to a tumor board
- twenty diagnostic tests in market like TruCheck for Indian market; uses liquid biopsy
- they are also tailoring diagnostic and treatment for India getting FDA fast track approvals
2:20-2:40
Co-targeting KIT/PDGRFA and Genomic Integrity in Gastrointestinal Stromal Tumors
Lori Rink, PhD, Associate Professor, Fox Chase Cancer Center
- GIST are most common nesychymal tumor in GI tract
- used to be misdiagnosed; was considered a leimyosarcoma
- very asymptomatic tumors and not good prognosis
- very refractory to genotoxic therapies
- RTK KIT/PDGFRA gain of function mutations
- Gleevec imatinib for unresectable GIST however vast majority of even responders become resistant to therapy and cancer returns
- there is a mutation map for hotspot mutations and sensitivity for gleevec
- however resistance emerged to ripretinib; in ATP binding pocket
- over treatment get a polyclonal resistance
- performed a kinome analysis; Wee1 looked like a potential target
- mouse studies (80 day) showed good efficacy
- avapiritinib ahs some neurotox and used in PDGFRA mut GIST model which is resistant to imitinib
- but if use Wee1 inhibitor with TKI can lower dose of avapiritinib
- cotargeting KIT/PDGFRA and WEE1 increases replicative stress
- they are using PDX models to test these combinations
- combination creates genomic instability
Real Time Conference Coverage: Advancing Precision Medicine Conference, Late Morning Session Track 1 October 4 2025
Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, Clinical & Translational, Clinical Diagnostics, Clinical Genomics, Conference Coverage with Social Media, FDA Regulatory Affairs, Genomic Expression, Genomic Testing: Methodology for Diagnosis, Healthcare costs and reimbursement, KRAS Mutation, Methylation, Personalized and Precision Medicine & Genomic Research, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, TP53 - Germline mutations, tagged anticancer drug resistance, biomarker panels, biomarker/companion diagnostics, Biomarkers & Medical Diagnostics, chemotherapy resistance, Commercialization, companion diagnostics, DNA methyation, Epigenetics, GlaxoSmithKline, precision oncology, Qiagen on October 4, 2025| Leave a Comment »
Real Time Conference Coverage: Advancing Precision Medicine Conference, Late Morning Session Track 1 October 4 2025
Reporter: Stephen J. Williams, PhD
Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at
using the following meeting hashtags
#AdvancingPM #precisionmedicine #WINSYMPO2025
SESSION 3
Advances in Precision Oncology:
From Genomics to Targeted Therapies
11:10-11:55
Breaking the Glass Ceiling: Targeting KRAS in Pancreatic Cancer
11:55-12:15
Charting the Future of Cancer Care: Precision Oncology and the Power of Genomics
12:15-12:35
Molecular Pathology as a Driver of Precision in Urological Cancers
12:30-12:40
Non – CME – dSTRIDE™-HR: A Functional Biomarker for In Situ, ‘real-time’ Detection and Quantification of Homologous Recombination Activity.
Magda Kordon-Kiszala, PhD, CEO and co-founder, intoDNA
12:35-12:55
Epigenetic Plasticity and Tumor Evolution: Mechanisms of Resistance in Precision Oncology
Johnathan R. Whetstine, PhD, Director, Cancer Epigenetics Institute, Director, Geonomics Resource, Fox Chase Cancer Center
- Title: Epigenetic plasticity a gatekeeper to generating extrachromosomal DNA amplification and rearrangements
- genetic events in cancer are actually controlled not random as he says
- Fox Chase Cancer Center Epigenetics Institute; 5th year goal to understand epigenetic mechanisms to understand resistance and biomarker development; bring others and break down silos; they are expanding and hiring and bringing into a network; March 5 2026 5th Annual Symposium Philadelphia Franklin Institute
- DNA amplification is also chromosomal: integrated same locus or different regions or chromosomal duplication
- KDM4A epigenetic demethylase controls transiet site specific DNA re-replication; can have focal control of DNA regions
- you can control regional control of like EGFR amplification
- can use Cy3 to find local regions
- KDM3B inhibitor promotes transiet copy gains in KMT2A/MLL
- EHMT2 is lysine demethylase is a driver of this copy amplification
- this demethylase can change expression locally in one hour.. very fast
- demethylases are very specific for their gene locus they control and so this demethylase only controls MLL gene
- doxorubicin topoisomerase inhibitor can cause LOH in MLL locus and methylase inhibitor can reverse this
- over twenty combinatorial regulators so this field is just budding
11:30-12:30
Companion Diagnostics in Hereditary and Chronic Diseases – Development, Regulatory Approval, and Commercialization – Non-CME Discussion
Huw Ricketts PhD, Senior Director, CLIA Business Development, QIAGEN
Tricia Carrigan, PhD, BC Biosolutions
Arushi Agarwal, MS, Partner, Health Advances
Melissa Reuter, MS, MBA, Director, Precision Medicine Program Strategy, GSK
- This is a session panel Discussion on the current state of companion diagnostic development, not just in oncology. Regulatory aspects will be discussed
- Arushi: There are alot of opportunities in non-oncology areas for companion diagnostics, and time to development may be an obstacle
- Huw Rickets: From a development standpoint most people are not looking at the diagnostic side but more on the therapeutic side.
- Tricia: There needs to be a shift in oncology drug development world, and pharma sees developing diagnostic is too expensive.
- Meliisa: They try to engage early with the agencies to understand the regulatory landscape; GSK is very strong in their oncology platform but there are gaps in diagnostics and non-oncology programs
- Arushi: seems in Pharma oncology and non-oncology programs seems siloed
- for non-oncology many of the biomarkers may be rare… well under 25% of population
- Huw: Qiagen trying to develop diagnostics for Parkinson’s but those rare genetic diseases are easier to develop
- Arushi: neurodegenerative, NASH, and immuno diseases are big areas where companies are looking to make companion diagnostics
- Huw: kidney disease is a big focus to develop companion diagnostics for
12:30-12:40
Non – CME – dSTRIDE™-HR: A Functional Biomarker for In Situ, ‘real-time’ Detection and Quantification of Homologous Recombination Activity.
Magda Kordon-Kiszala, PhD, CEO and co-founder, intoDNA
Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025
Posted in BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, BioTechnology - Venture Creation, Venture Capital, Cancer Informatics, Philanthropy to Academic Institution, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, Venture Capital, tagged : Immunotherapies, adverse events, Biotech Investment and Venture Growth: The Franchising of Intellectual Property as a Business Model, Brown University, cancer adverse event, Clinical Trials, early ventures, Immune checkpoint inhibitors, MD Anderson Cancer center, PD-1/PDL1, PDL-1 biomarker, philanthropy on October 3, 2025| 1 Comment »
Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session Track 1 October 3 2025
Reporter: Stephen J. Williams, PhD
Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at
using the following meeting hashtags
#AdvancingPM #precisionmedicine #WINSYMPO2025
WIN SYMPOSIUM
1:50-4:05
SESSION 4
From Targets to Trials:
Translating Discovery into Impact
1:50-2:10
Beyond Checkpoint Inhibitors: Targeted Immunotherapeutic Approaches for the Management of Solid Tumors
Matthew Hadfield, DO, Assistant Professor of Medicine, Phase 1 Clinical Trials, Cutaneous Malignancies, The Warren Alpert Medical School of Brown University
- we need to turn these immuno-cold tumors into immuno ‘hot’ tumors so immunotherapy will be effective and recognize them
- however each immunotherapies have their own toxicities
- immunocheck points inhibitors: 50% of patients get very rough adverse events and have to stop therapy and give immunosuppressives
- 60 yo female with urothelial carcinoma with chemo induced rash given pembrolizumab but got worse rash… had Steven Johnson Syndrome… fatal outcome from one cycle of PD-L1 inhibitor
- so now we are giving these immune checkpoints earlier before even surgery… the overall survival better but there are certain personalized toxicities
- up to 35% patients with cancer have chronic immuno related adverse events and dose limiting toxicities
- 50% have low grade multiple toxicities (and they treat these AEs with steroids)
- we have no biomarkers for these PD/PDL1 inhibitor adverse events
2:10-2:30
Implementing Molecular Profiling in Early Phase Clinical Trials: Precision from Bench to Bedside
- power of biomarkers: BRCA2 null women with ovarian cancer success with olaparib even though at time was not approved except the biomarker known
- every week they discuss with internal tumor board and consult with Foundation Medicine; however a mutational panel is great but need to understand the underlying effect on tumor biology
- there are a handful of tumor agnostic targeted agents: based on biomarkers
- she thinks digital twins will be helpful in determining cohort selection for clinical trails
- she would like multiomics to be performed on every patient but how would this be done, especially in the ecosystem of the USA
- from attendee question to speaker panel (from Indai): they have been running tmolecular boards but problem is when new targets or fusion proteins become known without a priori knowledge of them and no combination know what to do?
:30-2:40
Q&A
Matthew Hadfield, DO, Assistant Professor of Medicine, Phase 1 Clinical Trials, Cutaneous Malignancies, The Warren Alpert Medical School of Brown University
2:40-3:20
Non- CME Session: Venture Philanthropy
Eric Heil, MBA, Managing Partner, Medical Excellence Capital
- started a venture fund and then a 501(c) to give small grants
- in venture philanthropy it is not traditional grant writing but more of a personal relationship; he says find other companies they have backed and ask them
- all about networking
- looked at 1400 deals but only invested in 13
- back years ago his company biotech got ten million after 2009 from TAP but now it seems smaller bridge money
John Lehr, President & CEO, Parkinson’s Foundation
- runs venture philanthropy which is more like a mix of venture fund and granting agency
- most run a for profit venture but mix model with 501c to fund small grants
Dr. Blaine Robinson, PhD, Vice President of the Therapy Acceleration Program (TAP), Blood Cancer United
- runs Blood Cancer United that offers grants for blood based research
- they run three pillars: venture biotech funding, clinical trial funding, and academic research but most they take equity in biotechs
- so venture philanthropy is more of equity investing and using those funds to fund younger companies like bridge between first round and series C
- Blood Cancer United looking for million and above investment “first in class’; was early with Kite and UPenn (where are they now… are they still with them?)
3:20-4:10
eNSCLC Testing
- lung cancer has seemed to be ahead with respect to biomarkers and precision therapies
- at least with NCCN guidelines they are up to 14 therapeutic biomarkers not diagnostic biomarkers so very ahead on the clinical decision making on actionable mutations for lung cancer
- so most of the testing is genomic mutational spectrum for oncogenic drivers
- there are three protein based biomarkers: Met, PDL1,
- FISH is still used for some fusions
- NGS is more sensitive test but takes 2-4 weeks
- the number of detected EGFR variants are increasing so it is affecting the drug specificity
- recently NRG1 fusions have been approved as a heregulin HER3 biomarker;
- 15% which were detected as negative for fusions the patients actually responded because fusions were hard to detect; many false positives
- 76% did not meet MET eligbility but only 13% were high enough for MET marker but was enough for FDA approval
- some drugs beneficial for mutated version and some good for over expressed like MET or HER2 but where the mutation or exon skipping is important for therapy choice
- we need better biobanking because we need more tissue; we loose more tissue during sectioning and not splitting blocks into two (one for diagnostic one for therapeutic)
- liquid biopsy will find some mutations but other ones not very sensitivity in liquid biopsy like MET mutations (mutations may be assay specific)
- some muts in bone marrow may just be in aging progenitor cells and sometimes in oncogene like BRAF but not cancer but dlonal homatopoesis (increased risk for myeloproliferative diseases but not solid tumors like melanoma)
- clonal homatopoesis actually common so watch out when just relying on liquid biopsy
Conference Coverage 2025 Advancing Precision Medicine Conference, Philadelphia PA October 3-4 2025
Posted in Cancer Genomics, Cancer Informatics, Cardiovascular Pharmacogenomics, Circulating Tumor Cells (CTC), Clinical & Translational, Clinical Genomics, Conference Coverage with Social Media, Genomic Expression, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, tagged Advancing Precision Medicine, Biomarker discovery, biomarker panels, Cancer Genomics, cancer genomics and therapy, cardiogenomics, functional proteomics, liquid biopsy, Personalized and Precision Medicine & Genomic Research on October 2, 2025| 1 Comment »
Conference Coverage 2025 Advancing Precision Medicine Conference, Philadelphia PA October 3-4 2025
Reporter: Stephen J. Williams, PhD
The Annual Advanced Precision Medicine Conference will be held at the Pennsylvania Convention Center October 3-4 2025 in Philadelphia PA. Advancing Precision Medicine is an organization dedicated to provide education and discourse among medical professionals to advance the field of precision therapeutics and diagnostics in cancer, cardiovascular, and other diseases. The Annual symposium is held in Philadelphia.
The event will consist of two parallel tracks composed of keynote addresses, panel discussions and fireside chats which will encourage audience participation. Over the course of the two-day event leaders from industry, healthcare, regulatory bodies, academia and other pertinent stakeholders will share an intriguing and broad scope of content.
This event will consist of three immersive tracks, each crafted to explore the multifaceted dimensions of precision medicine. Delve into Precision Oncology, where groundbreaking advancements are reshaping the landscape of cancer diagnosis and treatment. Traverse the boundaries of Precision Medicine Outside of Oncology, as we probe into the intricate interplay of genetics, lifestyle, and environment across a spectrum of diseases and conditions including rare disease, cardiology, ophthalmology, and neurodegenerative disease. Immerse yourself in AI for Precision Medicine, where cutting-edge technologies are revolutionizing diagnostics, therapeutics, and patient care. Additionally, explore the emerging frontiers of Spatial Biology and Mult-Omics, where integrated approaches are unraveling the complexities of biological systems with unprecedented depth and precision.
https://www.advancingprecisionmedicine.com/
Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at
using the following meeting hashtags
#AdvancingPM #precisionmedicine #WINSYMPO2025
APM is a mission-driven team dedicated to advancing clinical practice through education in precision medicine, oncology, and pathology. Our expert-led programs bring together clinicians, pathologists, pharmacists, nurses, and researchers from across the country.
What We Offer
In 2025, we’re proud to offer three specialized event series—each tailored to a different corner of the healthcare ecosystem:
Register here for the 2025 Conference: https://www.advancingprecisionmedicine.com/apm-home/apm-annual-conference-and-exhibition-in-philadelphia/
Where discovery meets application – and science transforms lives.
What’s New in 2025?
Four Specialized Tracks:
Track 1 – 2025 WIN Symposium: Progress and Challenges in Precision Oncology
Presented in partnership with Advancing Precision Medicine
As the official 2025 WIN Symposium, this dedicated track will explore the evolving landscape of precision oncology, highlighting both groundbreaking advances and the ongoing challenges of translating molecular insights into clinical impact. Curated by the WIN Consortium, the program will feature global leaders in cancer research, diagnostics, and therapeutic innovation—offering a comprehensive view of how precision medicine is reshaping oncology across tumor types and care settings.
Track 2 – Day 1 – Multi-Omics Integration, Day 2 – Precision Medicine Outside of Oncology
From genomics and transcriptomics to proteomics and metabolomics—this track highlights how multi-layered data is revolutionizing systems biology and clinical decision-making.
Diving into applications across cardiovascular, neurology, rare disease, infectious disease, and other therapeutic areas where precision tools are reshaping clinical practice.
Why Attend?
- Cutting-Edge Innovation: Explore AI-powered solutions, multi-omics workflows, clinical trial design, and real-world implementation.
- Renowned Speakers: Hear from global thought leaders in translational research, biotech innovation, and personalized therapeutics.
- Dynamic Format: Keynotes, fireside chats, panels, and audience-interactive discussions across four concurrent tracks.
- Unmatched Networking: Collaborate with scientists, startups, executives, regulators, and investors shaping tomorrow’s care.
- Philadelphia Advantage: Centrally located near premier academic institutions, hospitals, incubators, and venture capital networks.
Who Should Attend?
Researchers, clinicians, data scientists, regulatory experts, startup founders, investors, tech transfer professionals, and healthcare leaders.
Let’s advance a future that is more predictive, preventive, and precise—together.
2019 Nobel Laureate
Sidney Farber Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute
Senior Physician-Scientist at Brigham and Women’s Hospital
Howard Hughes Medical Institute Investigator
William Kaelin is the Sidney Farber Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, Senior Physician-Scientist at Brigham and Women’s Hospital and Howard Hughes Medical Institute Investigator. He obtained his undergraduate and M.D. degrees from Duke University and completed his training in Internal Medicine at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in Medical Oncology at the Dana-Farber Cancer Institute and later a postdoctoral fellow in David Livingston’s laboratory, during which time he was a McDonnell Scholar.
A Nobel Laureate, Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the National Academy of Medicine, the American Society of Clinical Investigation, and the American College of Physicians. He previously served on the National Cancer Institute Board of Scientific Advisors, the AACR Board of Trustees, and the Institute of Medicine National Cancer Policy Board. He is a recipient of the Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center; the Richard and Hinda Rosenthal Prize from the AACR; the Doris Duke Distinguished Clinical Scientist award; the 2010 Canada International Gairdner Award; ASCI’s Stanley J. Korsmeyer Award; the Scientific Grand Prix of the Foundation Lefoulon-Delalande; the Wiley Prize in Biomedical Sciences; the Steven C. Beering Award; the AACR Princess Takamatsu Award; the ASCO Science of Oncology Award; the Helis Award; the Albert Lasker Basic Medical Research Prize; the Massry Prize; the Harriet P. Dustan Award for Science as Related to Medicine from the American College of Physicians.
Dr. Kaelin’s research seeks to understand how, mechanistically, mutations affecting tumor-suppressor genes cause cancer. His laboratory is currently focused on studies of the VHL, RB-1, and p53 tumor suppressor genes. His long-term goal is to lay the foundation for new anticancer therapies based on the biochemical functions of such proteins. His work on the VHL protein helped to motivate the eventual successful clinical testing of VEGF inhibitors for the treatment of kidney cancer. Moreover, this line of investigation led to new insights into how cells sense and respond to changes in oxygen, and thus has implications for diseases beyond cancer, such as anemia, myocardial infarction, and stroke. His group also showed that leukemic transformation by mutant IDH was reversible, setting the stage for the development and approval of mutant IDH inhibitors, and discovered how thalidomide-like drugs kill myeloma cells by degrading two otherwise undruggable transcription factors,
2025 Steering Committee
Presentations
A diverse group of more than 90 key opinion leaders will convene to explore the critical forces shaping the future of healthcare. Representing a range of disciplines—including genomics, bioinformatics, clinical research, biopharma, technology, and investment—these experts will lead discussions on the latest advancements and challenges in precision medicine.
Topics will include the evolution of genomic sequencing technologies, ethical considerations in managing patient data, the integration of AI in diagnostics, and strategies for translating innovation into clinical practice. The inclusion of investors and strategic partners will also bring a vital perspective on funding models, commercialization pathways, and the acceleration of cutting-edge therapies. Together, these voices will offer a comprehensive view of the trends transforming personalized healthcare on a global scale.
Networking Opportunities
Our precision medicine event, hosting over 500 attendees, offers invaluable networking opportunities. Bringing together professionals, researchers, and industry leaders, the event facilitates engaging discussions, knowledge-sharing, and potential partnerships, driving advancements in precision medicine.
Why Exhibit
Exhibiting at the event provides a unique opportunity to showcase your cutting-edge solutions and connect with key stakeholders in the rapidly advancing field of personalized healthcare. As an exhibitor, you’ll gain visibility among industry leaders, researchers, and professionals, allowing you to forge strategic partnerships, highlight your contributions to precision medicine, and stay at the forefront of innovations shaping the future of healthcare. Don’t miss the chance to position your company as a leader in this dynamic and transformative space, driving meaningful collaborations and contributing to the advancement of precision medicine.
THE LOCATION
APM Annual Conference 2025
Pennsylvania Convention Center
1101 Arch Street
Philadelphia, PA 19107
Registration Fees
Student – free
Academic/Government/Non-Profit – free
Healthcare Providers – free
Investors – free
Vendor/Technology Provider $999
Other Live Conference Proceedings can be found on this Online Open Access Journal at:
including a list of previous conference at:
Part Two: List of BioTech Conferences 2013 to Present
including Live Coverage of the 2024 Advancing Precision Medicine conference at:
Real Time Coverage Advancing Precision Medicine Annual Conference, Philadelphia PA November 1,2 2024
Shaping the Future: The Rise of Structural Nanomedicine
Posted in Cancer and Current Therapeutics, Efficacy of Anti-Tumor T Cells, Nanotechnology for Drug Delivery, Patient-centered Medicine, Personalized and Precision Medicine & Genomic Research, Personalized Medicine Coalition, Population Health Management, Genetics & Pharmaceutical, Precision Cancer Medicine, tagged Efficacy, nano particles, nanomedicine, side effects, treatment on May 2, 2025| Leave a Comment »
Shaping the Future: The Rise of Structural Nanomedicine
Curator: Dr. Sudipta Saha, Ph.D.
In their 2025 review, Mirkin, Mrksich, and Artzi describe how the field of structural nanomedicine is being transformed to revolutionize biomedical science. Therapeutic materials are now being designed with precise nanoscale architectures to optimize biological interactions, improve efficacy, and reduce side effects.
It is explained that, unlike traditional drug delivery methods, structural nanomedicine is centered on the engineering of form and function at the molecular level. Advances in DNA and RNA nanotechnology, self-assembling peptide systems, and engineered nanoparticles have been utilized to create customizable platforms capable of navigating complex biological environments. These structures are being programmed to respond to specific physiological triggers, thereby enabling targeted delivery and controlled release.
A strong emphasis is placed on how rational design principles—borrowed from materials science, chemistry, and bioengineering—are driving innovation. Examples are presented where precisely constructed nanostructures have been shown to outperform conventional therapies in cancer treatment, immunomodulation, and regenerative medicine.
Attention is drawn to the challenges that must still be addressed, including the scalability of manufacturing, regulatory barriers, and the need for deeper insights into nano-bio interactions at the systems level. It is argued that interdisciplinary collaboration will be required for the successful translation of structural nanomedicine from laboratory research to clinical application.
Ultimately, structural nanomedicine is portrayed as a paradigm shift—where passive carrier systems are being replaced by dynamic, functional architectures that actively engage in therapeutic processes. Optimism is expressed that through continued technological convergence, a new generation of precision therapies tailored to individual patients will be realized.
This review is recommended for researchers, clinicians, and industry professionals seeking to remain informed about future directions in biomedical innovation.
References
https://www.nature.com/articles/s44222-025-00306-5
https://www.nature.com/articles/s41551-019-0351-1
https://www.nature.com/articles/382607a0
https://pubs.acs.org/doi/10.1021/acsnano.3c06564
https://www.nature.com/articles/s41565-023-01447-7
Follow Blog via Email
Join 2,041 other subscribers-
Recent Posts
- Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI in Health, Life Sciences & BioPharma June 15, 2026
- Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
- A Systematic Analysis of Competitive Dynamics in the AI Revolution — Strategic Relevance to LPBI Group’s Mission – Alex Wissner-Gross Daily Newsletters by KOL (March 1 – June 10, 2026, to be extended to Present) June 11, 2026
- In Memoriam: Professor Yitzhak Apeloig, President and Distinguised Professor of the Technion June 4, 2026
- Top VC Investors in AI / Health AI in 2026 May 26, 2026
- Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UC, Berkeley, 1983. January 31, 2026
- 2026 World Economic Forum, 1/19 – 1/23/2026, Davos, Switzerland, LPBI Group’s KOLs interpretation of AI in Health Videos January 24, 2026
- Evolving LPBI Group’s Portfolio of Intellectual Properties (IP): From 2021 Vision to 2026 Reality January 12, 2026
- Aviva Lev-Ari, PhD, RN – Biography ->> Grokepedia Entry January 11, 2026
- List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
Archives
Categories
Meta
2012pharmaceutical
sjwilliamspa